Neuvogen — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Neuvogen is a private, preclinical-stage biotech founded in 2015 and headquartered in San Diego, CA, USA. The company is pioneering a novel whole tumor cell vaccine platform designed to overcome the heterogeneity of solid tumors by eliciting a broad, multi-antigen T-cell response. Led by a team with expertise in oncology, immunology, and biotech finance, Neuvogen aims to create accessible, off-the-shelf vaccines that can be integrated into standard care to prevent relapse. The company is currently in the preclinical development phase and is pre-revenue.

OncologySolid Tumors

Technology Platform

Proprietary whole tumor cell vaccine platform with a specialized activation technology designed to deliver a broad immune response against a wide and diverse set of tumor antigens, targeting tumor heterogeneity.

Opportunities

The large and growing market for solid tumor therapies, particularly in the adjuvant setting to prevent relapse, represents a major opportunity.

An effective, off-the-shelf vaccine could be more scalable and accessible than personalized approaches, allowing for broader patient reach and integration into standard care pathways.

Risk Factors

High scientific risk that the platform's preclinical promise will not translate to clinical efficacy and safety.

Significant financial risk as a pre-revenue company requiring substantial capital to reach clinical milestones.

Intense competition from numerous other modalities in the cancer vaccine and immuno-oncology space.

Competitive Landscape

Neuvogen competes in the crowded cancer vaccine space against companies developing mRNA-based vaccines (e.g., BioNTech, Moderna), personalized neoantigen vaccines, and other cell-based immunotherapies. Its key differentiator is the breadth of antigen targeting via its whole cell approach, positioned against the more targeted nature of many neoantigen platforms.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →